Explicyte CEO Alban Bessède will be speaking at the CONDOR Symposium on September 25 in Bordeaux. In a joint session with Prof. Antoine Italiano, he will present findings from the CONGRATS study (Phase II trial of nivolumab ± relatlimab in patients with TLS-positive soft-tissue sarcomas). Alban’s talk will focus on spatial transcriptomic data revealing molecular patterns linked to sensitivity and resistance to immunotherapy in sarcoma.